Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-finding study of LIK066 in Japanese patients with obesity
jRCT2080223753Phase 2Completed
- Sponsor
- Novartis
- Start
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of licogliflozin in obesity, type 2 diabetes mellitus (T2DM) and impaired fasting glucose (IFG) (5 arms), sponsored by Novartis. Primary endpoint: Change in body weight at 12 weeks. Started Dec 2017; status: completed.
02
Drugs
licogliflozin
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)impaired fasting glucose (IFG)
Beyond the preview
Go deeper on jRCT2080223753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223753.